Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Overweight, Obesity, Weight Loss Maintenance
Interventions: Behavior Therapy, Meal Replacements, Nutritrol; Behavioral · Dietary Supplement
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions: NKTR-118, Ketoconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Venous Thromboembolism
Interventions: Photoacoustic flow cytometry device; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 100
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more

Conditions: Anaplastic Astrocytoma, Glioblastoma
Interventions: trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine; Drug · Device · Procedure
Lead sponsor: Isarna Therapeutics GmbH; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Edison, New Jersey • Mineola, New York • Rochester, New York

Conditions: Solid Tumor, Adult
Interventions: CRB-701, Anti-PD-1; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • San Diego, California + 12 more

Conditions: Healthy Volunteer
Interventions: CC-122, Itraconazole, Fluvoxamine, Rifampin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Transplant; Failure, Kidney
Interventions: Alemtuzumab, Daclizumab, Thymoglobulin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Stroke
Interventions: Repetitive Peripheral Magnetic Stimulation (rPMS), Sham Priming; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more

Conditions: Malignant Pleural Mesothelioma, Solid Tumors
Interventions: pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin, pemetrexed, cisplatin and CBP501, dose finding; Drug
Lead sponsor: CanBas Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 9 more

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin 50 mg, Canagliflozin 100 mg, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions: iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2040
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Nonalcoholic Steatohepatitis, NASH
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more

Conditions: Diabetes Mellitus
Interventions: JTT-252 or Placebo, JTT-252; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Austin, Texas

Conditions: Tobacco Use, Smoking, Smoking Cessation
Interventions: Cognitive-Motivational Feedback, Staff Tobacco Quit Line Referral Implementation Support, Consumer Incentives for Immediate Referral to a Tobacco Quit Line; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Non-small Cell Lung Cancer
Interventions: Blueberry powder; Dietary Supplement
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Stroke
Interventions: Lifestyle Management Program, Post-stroke Optimization of Walking using Explosive Resistance; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 35 Years to 85 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Asthma
Interventions: Environmental Intervention; Other
Lead sponsor: Columbia University; Other
Eligibility: 6 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Prostate Cancer
Interventions: REGN5678, Cemiplimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Disease
Interventions: Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells; Drug · Device
Lead sponsor: Marianne Yee; Other
Eligibility: 2 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Human Papillomavirus (HPV) Vaccines
Interventions: Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

A Test of Nutritional Interventions to Enhance Weight Loss Maintenance

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

Detecting Circulating Emboli in Patients with Acute Venous Thromboembolism

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

The Effect of rPMS on Motor Skill Performance in Persons With a Stroke.

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Salvation Army Tobacco Quit Line Referral Implementation Trial

Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

EMPOWER: Effects of Weight Loss and Exercise Post-stroke

Environmental Intervention Versus Standard Care to Reduce Pharmacologic Therapy for Asthma

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Biotin-RBC Transfusion in SCD

Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial